Articles

Videos

Podcasts

Clinical

On this week's episode, Suzy is joined by Michelle Henry, MD, from Skin & Aesthetic Surgery of Manhattan, a board-certified dermatologist located in New York.

Pharmacist Moms: Coffee With Suzy - Episode 13

Laly Havern, PharmD, MS, BCACP, director in specialty health solutions leading in oncology and fertility at Walgreens, discusses the company's Fertility Awareness Campaign that is being launched as part of National Infertility Awareness Week.

Walgreens Launches Fertility Awareness Campaign in Support of National Infertility Awareness Week

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

California Requires State Universities to Offer Access to Medication Abortion on Campus

Premsyn PMS temporarily relieves symptoms associated with premenstrual syndrome.

Daily OTC Pearl: Premsyn PMS

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

Hepatitis C Is Widespread but Rarely Treated in Postpartum Medicaid Beneficiaries With OUD

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

Endocrine Therapy May Benefit Women in Postmenopause as Much as Chemoendocrine

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Women Are Less Likely to Receive Life-Saving Heart Procedures, Study Results Show

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

FDA Approves Pembrolizumab for MSI‑H/dMMR Advanced Endometrial Carcinoma

Our first on-location podcast episode featuring 2 prolific women in the pharmacy world! 

BONUS: APhA 2022 feat. Christina Madison and Hillary Blackburn

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors 

® Women's Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health conditions that affect women, including gynecological health and maternal health.